Tirzepatide
The active medication: a dual GIP + GLP-1 receptor agonist, taken once a week.
Choose the path that fits you.
All-in-one plan
Illustrative image; actual packaging may vary. CAPO Health is not a pharmacy. If prescribed, your medication is prepared by a state-licensed 503A compounding pharmacy; your pharmacy label shows the concentration and directions prescribed for you.
Compounded · GIP + GLP-1 injection
Care built around your file.
Provider-guided care with an individual prescription, ongoing follow-up and delivery from a state-licensed compounding pharmacy, if a provider prescribes it for you.
Your plan
$199/month equivalent
Same price at every prescribed dose · final price confirmed after your provider's review
Choose your plan
On 3-, 6- and 12-month plans, at checkout. Subject to eligibility.Payment is collected at checkout, before a licensed provider reviews your file. If treatment is not appropriate for you, nothing is dispensed and your order is refunded in full. No separate enrollment, consultation or membership fees.
Compounded medications are not approved by the FDA. The FDA does not review them for safety, effectiveness or quality. Treatment requires an individual evaluation and a prescription. Important Safety Information
Prescription only if a licensed provider determines it is clinically appropriate. Not everyone qualifies. Individual results vary.
Potential benefits
Tirzepatide works on two hormones your body uses after meals, GIP and GLP-1. As part of a provider-guided plan with healthier eating and more activity, it may help you:
Acts on two hormone receptors, GIP and GLP-1, involved in appetite and metabolism.
Quiet constant thoughts about food, so healthier choices feel easier.
Feel satisfied with smaller portions, for longer.
Work toward weight loss at a gradual pace your provider sets. No crash dieting.
Your care team helps you manage common effects like nausea.
Your provider checks in and adjusts your dose as your body responds.
Individual results vary. Benefits are not guaranteed and depend on your provider's evaluation and your plan.
Why it matters
It's not just willpower. Hunger hormones, metabolism and genetics push back when you try to lose weight, and excess weight affects much more than how you feel.
A licensed provider reviews your history and decides whether a GLP-1 medication is right for you.
What does it do
Individual results vary.
Your formulation
Compounded tirzepatide, prepared with one supporting ingredient — vitamin B12 or glycine. Your provider chooses the formulation that fits your file.
The active medication: a dual GIP + GLP-1 receptor agonist, taken once a week.
An amino acid your body uses to build protein. May support muscle maintenance while you eat less.
A vitamin involved in energy metabolism and red blood cell formation. May help maintain nutrient balance while you eat less.
Your provider determines the formulation, strength and directions that are appropriate for you. Personalized options are not guaranteed.
From first question to follow-up
Complete the online assessment with your history, medications and goals, choose a plan and check out.
A provider licensed in your state reviews your file and decides whether treatment is appropriate. If it is not, your order is refunded in full.
If prescribed, your medication is compounded by a state-licensed pharmacy and shipped to you. Check-ins continue through your portal.
Understanding your options
Compounded tirzepatide is one option among several. Your provider weighs your medical history, your other medications and your goals before recommending it, a different medication or no treatment at all.
Also exploring your options? Learn about Compounded Semaglutide
Compounded treatment is meant for cases where an FDA-approved medicine cannot meet a patient's medical needs, as determined by the provider.
Your prescription and your measuring instructions are specific to you. Your care team reviews how you respond and answers questions along the way.
Screening tool
BMI uses your height and weight to estimate whether your weight falls within a healthy range for your height — one of the first things a provider looks at before considering tirzepatide.
Your BMI
Enter your height and weight to see your result.
*BMI does not directly measure body fat and may not accurately reflect health for people with high muscle mass, pregnant women, children, older adults and some ethnic groups. It is a screening tool, not a diagnosis, and it does not determine eligibility. Providers generally consider GLP-1 therapy for adults with a BMI of 30 or more, or 27 or more with a weight-related condition.
Pharmacy & compliance
If a provider prescribes treatment, your medication is prepared by a state-licensed compounding pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, and shipped to your door.
Our partner pharmacy is The Pharmacy Hub (Miami, FL). CAPO Health is not a pharmacy and does not compound, manufacture or dispense medications. Availability of certain medications or formulations can vary by state.
Illustrative image
Before you begin
A little clarity goes a long way.
No. Compounded tirzepatide is prepared by a U.S. state-licensed pharmacy for an individual patient under a provider's prescription. The FDA does not review or approve compounded drugs for safety, effectiveness or quality, and compounded tirzepatide is not a generic of, or equivalent to, any branded medication.
Usually not. Providers start low and increase the dose in steps, usually no more often than every four weeks, because most side effects appear when starting or raising the dose. If you are switching from another provider, share your current medication and dose in the intake.
Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and stomach pain are the most common, mostly when starting or increasing the dose. Serious side effects are rare but possible — read the Important Safety Information on this page before starting.
It can. Tirzepatide may make birth control pills less effective. Your provider may recommend a non-oral or barrier method for four weeks after you start and for four weeks after each dose increase.
Tirzepatide acts on two hormone receptors (GIP and GLP-1); semaglutide acts on one hormone receptor (GLP-1). Your provider recommends one, or neither, based on your health history, goals and any medication you already take.
If the licensed provider decides that treatment is not appropriate for you, you are notified with the reason and no medication is dispensed. Any amount you have already paid is refunded in full to your original payment method. Not everyone qualifies, and the provider may recommend a different path.
Compounded tirzepatide is not approved by the FDA, and the FDA does not review it for safety, effectiveness or quality. Nausea, vomiting, diarrhea, constipation and abdominal discomfort can occur, most often when starting or raising a dose.
Serious risks include pancreatitis, gallbladder disease, dehydration-related kidney injury and severe allergic reactions. Approved tirzepatide labeling carries a boxed warning about thyroid C-cell tumors based on animal studies; the risk in humans is unknown. Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
Review every medicine you take and any pregnancy plans with your provider. Tirzepatide can affect how oral contraceptives work, and some diabetes medicines raise the risk of low blood sugar. Seek urgent care for severe abdominal pain or trouble breathing. Read the full safety information below.
The online visit takes just a few minutes. If a licensed provider decides treatment isn't right for you, nothing is dispensed and you're refunded in full.
Questions? Call us at 1-833-772-7117
Individual results vary. Illustrative image.Important Safety Information
Compounded tirzepatide is prepared for an individual patient by a U.S. pharmacy licensed in the state where it dispenses, under a prescription from a licensed provider. Federal law permits compounded drugs to be prescribed, but they are not FDA-approved, and the FDA does not review them for safety, effectiveness or manufacturing quality. Compounded tirzepatide is not a generic version of, or equivalent to, any branded medication. Prescription required. Not everyone qualifies. Individual results vary.
In rodent studies, tirzepatide caused thyroid C-cell tumors. It is not known whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in people. Do not use tirzepatide if you or a family member has ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider right away if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. When prescribed for weight management it is used together with a reduced-calorie diet and increased physical activity in adults with obesity, or with overweight and at least one weight-related medical condition. Whether it is appropriate for you is decided by your licensed provider after reviewing your health history. It should not be combined with other GLP-1 medicines and is not for people with type 1 diabetes.
Once a week, on the same day each week, as a subcutaneous injection under the skin of the abdomen, thigh or upper arm. Your provider starts at a low dose and increases it in steps, usually no more often than every four weeks, according to how you tolerate it. Use a new needle for every injection and never share vials or needles.
Tirzepatide should not be used during pregnancy and may harm an unborn baby. Tell your provider if you become pregnant or plan to. It is not known whether tirzepatide passes into breast milk; discuss feeding options with your provider.
Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, stomach pain, tiredness, belching, heartburn, hair loss and reactions at the injection site. Digestive symptoms are most common when starting or increasing the dose and often ease over time. This is not a complete list.
This summary does not replace the full prescribing information and is not medical advice. Discuss every risk and benefit with your licensed provider before starting or changing treatment. If you experience a serious side effect, contact your provider; in an emergency, call 911. Suspected adverse reactions can also be reported to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Individual results vary.
Compounded Tirzepatide is compounded by a state-licensed pharmacy under Section 503A of the Federal Food, Drug, and Cosmetic Act and is dispensed only with a patient-specific prescription issued after a medical evaluation. It is not approved by the FDA and is not a generic version of, or equivalent to, any branded medication. Pricing shown on this page reflects current plan prices; your provider confirms your plan and final price after review, and if no prescription is issued your order is refunded in full. Individual results vary.
CAPO Health is a technology platform. CAPO Health is not a pharmacy and does not practice medicine. Medical services are provided by independent, state-licensed healthcare providers who exercise their own clinical judgment. Prescriptions are issued only after a provider reviews your information and determines that treatment is appropriate for you. Not everyone qualifies, and no treatment, outcome or eligibility is guaranteed.
Most medications referenced on this site are compounded preparations prepared by U.S. pharmacies licensed in the state where they dispense. Compounded drugs are not approved by the FDA and are not evaluated by the FDA for safety, effectiveness or quality. They are not generic versions of, or equivalent to, any branded medication. Some medications, such as oral tablets, may be dispensed as commercially manufactured products; your pharmacy label shows what was dispensed. Clinical evidence for wellness uses of NAD+, Lipo-B and glutathione is limited.
GLP-1 receptor agonists carry risks, including but not limited to nausea, vomiting, diarrhea, constipation, pancreatitis, gallbladder disease and, in animal studies, thyroid C-cell tumors. Discuss your full medical history, including any personal or family history of medullary thyroid carcinoma or MEN 2, with your provider. Every other treatment carries its own risks: PDE5 inhibitors must never be combined with nitrates. Read the Important Safety Information on each treatment page. This website does not provide medical advice and is not a substitute for consultation with a qualified clinician. In an emergency, call 911.
Weight figures, timelines and projections shown anywhere on this page are illustrative and drawn from published clinical literature, not from CAPO Health patient outcomes. Individual results vary. Your provider confirms the plan after review; if no prescription is issued, any amount paid is refunded in full. Product-specific risks, contraindications and side effects are listed in the Important Safety Information for each medication, available from every treatment card and from the footer. This site collects no protected health information — intake happens inside the secure, HIPAA-compliant patient portal.
People pictured on this site are illustrative images, not CAPO Health patients. They do not describe anyone's treatment experience and do not depict the results of any medication. Individual results vary.